Eli Lilly and Co. is funding and participating in an Indiana University study that examines the health outcomes of people on weight loss drugs, including Lilly medications.

Record performance of its GLP-1 drugs sent shares in Eli Lilly soaring almost 4% after its earnings call on Thursday.

Eli Lilly’s stock rallies, as Zepbound sales nearly tripled, leading to record revenue and a raised full-year outlook.

As obesity drug heavyweights Eli Lilly and Novo Nordisk gear up to release results for the third quarter, investors are looking elsewhere: high-stakes price talks with U.S. President Donald Trump.

With a market cap of around $730 billion, Eli Lilly ( LLY 0.92%) is one of the largest pharmaceutical companies on planet Earth. It has a strong position in the emerging niche of weight loss drugs, with patent protections that extend into the mid-2030s. And there's a solid pipeline of drugs coming up, too.

An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner Innovent has bested Novo Nordisk’s reigning GLP-1 semaglutide in a phase 3 study across both b | Innovent's Eli Lilly-partnered mazdutide,